Ocrevus and Calcinosis - a phase IV clinical study of FDA data

Summary:

Calcinosis is reported as a side effect among people who take Ocrevus (ocrelizumab), especially for people who are female, 50-59 old, also take Pantoprazole, and have Relapsing-remitting multiple sclerosis.

The phase IV clinical study analyzes which people have Calcinosis when taking Ocrevus. It is created by eHealthMe based on reports of 56,539 people who have side effects when taking Ocrevus from the FDA, and is updated regularly.

What is Ocrevus?

Ocrevus has active ingredients of ocrelizumab. eHealthMe is studying from 56,583 Ocrevus users. Check the latest studies of Ocrevus.

What is Calcinosis?

Calcinosis (calcium deposits in any soft tissue) is found to be associated with 418 drugs and 859 conditions by eHealthMe. Check the latest studies of Calcinosis.

On Jul, 12, 2026

56,539 people reported to have side effects when taking Ocrevus.
Among them, 42 people (0.07%) have Calcinosis.

Among these 42 people:

What is the gender of people who have Calcinosis when taking Ocrevus? *

female: 100 %
male: 0.0 %

What is the age of people who have Calcinosis when taking Ocrevus? *

What are other drugs people take besides Ocrevus? *

Pantoprazole: 28 people, 66.67%
Ibuprofen: 23 people, 54.76%
Albuterol: 23 people, 54.76%
Oxycodone: 21 people, 50.00%
Triamcinolone Acetonide: 19 people, 45.24%
Folic Acid: 14 people, 33.33%
Novalgin: 10 people, 23.81%
Heparin: 8 people, 19.05%
Ramipril: 8 people, 19.05%
Nitrofurantoin: 8 people, 19.05%

What are other side effects people have besides Calcinosis? *

Weakness: 35 people, 83.33%
Cataract (clouding of the lens inside the eye): 32 people, 76.19%
Hair Loss: 32 people, 76.19%
Dry Skin: 32 people, 76.19%
Weight Increased: 32 people, 76.19%
Cushing's Syndrome (obesity, a rounded face, increased fat): 32 people, 76.19%
Dizziness: 31 people, 73.81%
Insomnia (sleeplessness): 29 people, 69.05%
B-Lymphocyte Count Decreased: 27 people, 64.29%
Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 27 people, 64.29%

What are the existing conditions these people have? *

Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 35 people, 83.33%
Secondary Progressive Multiple Sclerosis (a stage of ms which comes after relapsing remitting ms in many cases): 20 people, 47.62%
Urinary Tract Infection: 7 people, 16.67%
Nasopharyngitis (inflammation of the nasopharynx): 7 people, 16.67%
Primary Progressive Multiple Sclerosis (primary progressive inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 6 people, 14.29%
Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 5 people, 11.90%
Progressive Relapsing Multiple Sclerosis (chronic autoimmune disease of the central nervous system in which gradual destruction of myelin occurs in patches throughout the brain or spinal cord or both): 5 people, 11.90%
Muscle Spasticity (tight or stiff muscles and an inability to control those muscles): 5 people, 11.90%
Sleep Disorder: 4 people, 9.52%
Stress And Anxiety: 2 people, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Ocrevus and have Calcinosis?

- Check whether Calcinosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Ocrevus:

Ocrevus (56,583 reports)

Calcinosis treatments and more:

Calcinosis (3,651 reports)

Browse all side effects of Ocrevus:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Calcinosis:

Calcinosis (418 drugs)

Browse all the conditions that are associated with Calcinosis:

Calcinosis (859 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ocrelizumab (the active ingredients of Ocrevus) and Ocrevus (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.